US Bancorp DE Acquires 4,383 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

US Bancorp DE lifted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 1,889.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,615 shares of the company’s stock after buying an additional 4,383 shares during the quarter. US Bancorp DE’s holdings in Castle Biosciences were worth $132,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Castle Biosciences by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after purchasing an additional 2,093 shares in the last quarter. First Bank & Trust bought a new position in Castle Biosciences in the 3rd quarter worth approximately $261,000. Creative Planning bought a new position in Castle Biosciences in the 3rd quarter worth approximately $299,000. Inspire Investing LLC lifted its holdings in Castle Biosciences by 14.4% during the 3rd quarter. Inspire Investing LLC now owns 42,516 shares of the company’s stock worth $1,213,000 after buying an additional 5,349 shares in the last quarter. Finally, Truist Financial Corp increased its stake in shares of Castle Biosciences by 20.5% in the 2nd quarter. Truist Financial Corp now owns 14,217 shares of the company’s stock valued at $310,000 after buying an additional 2,420 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Transactions at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.44, for a total value of $231,604.48. Following the sale, the director now directly owns 5,700 shares in the company, valued at $167,808. The trade was a 57.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the transaction, the insider now owns 94,622 shares of the company’s stock, valued at approximately $2,718,490.06. The trade was a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,290 shares of company stock valued at $545,468 over the last quarter. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Trading Down 8.9 %

Shares of NASDAQ CSTL opened at $28.10 on Friday. Castle Biosciences, Inc. has a twelve month low of $16.97 and a twelve month high of $35.84. The stock has a market cap of $787.08 million, a price-to-earnings ratio of 144.46 and a beta of 0.99. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average is $31.16 and its 200-day moving average is $26.21.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The firm had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. During the same period in the previous year, the company posted ($0.26) earnings per share. Equities research analysts predict that Castle Biosciences, Inc. will post -0.08 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Lake Street Capital lifted their price objective on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Robert W. Baird lifted their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. KeyCorp increased their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research report on Tuesday, August 6th. Finally, BTIG Research raised their price target on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $37.88.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.